Results 31 to 40 of about 11,456 (188)

Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Sodium‐glucose cotransporter‐2 inhibitors are cardioprotective independent of glucose control, as demonstrated in animal models of acute myocardial ischemia and clinical trials.
Sharif A. Sabe, Cynthia M. Xu, Mohamed Sabra, Dwight Douglas Harris, Akshay Malhotra, Ahmed Aboulgheit, Madigan Stanley, M. Ruhul Abid, Frank W. Sellke   +8 more
doaj   +1 more source

Canagliflozin Increases Intestinal Adenoma Burden in Female Apc(Min/+) Mice

, 2021
The diabetes drug canagliflozin extends life span in male mice. Since malignant neoplasms are the major cause of death in most mouse strains, this observation suggests that canagliflozin might exert anti-neoplastic effects in male mice.
Greenson, Joel K, Miller, Richard A, Lombard, David B, Miller, Richard A., Skinner, Mary E., Greenson, Joel K., Basu, Jookta, Korfhage, Justin, Skinner, Mary E, Lombard, David B.   +9 more
core   +1 more source

Effects of canagliflozin on human myocardial redox signalling: clinical implications [PDF]

, 2021
Aims Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2
Sommariva, Elena, Stadiotti, Ilaria, Carena, Maria C, Casadei, Barbara, Channon, Keith M, Reus, Elsa Mauricio, Chuaiphichai, Surawee, Shirodaria, Cheerag, Krasopoulos, George, Badi, Ileana, Antonopoulos, Alexios S, Farid, Shakil, Sayeed, Rana, Polkinghorne, Murray, Oikonomou, Evangelos K, Akoumianakis, Ioannis, Kotanidis, Christos P, Akawi, Nadia, Antoniades, Charalambos, Kondo, Hidekazu, Srivastava, Vivek   +20 more
core   +4 more sources

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial.
Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine   +20 more
doaj   +1 more source

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice [PDF]

, 2020
Aim: Recent studies have demonstrated that selective sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, although their mechanism remains obscure.
Yagi, Shusuke, Salim, Hotimah Masdan, Kusunose, Kenya, Rahadian, Arief, Yamada, Hirotsugu, Fukuda, Daiju   +5 more
core   +1 more source

Relationship between canagliflozin use and sarcopenia: Real-world data from the United States

Diabetes Epidemiology and Management
Aims: Real-world data were analyzed to evaluate the incidence and risk of sarcopenia for canagliflozin compared with other antihyperglycemic agents (AHAs) including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-
Zhong Yuan, Jill Hardin, James P. Gilbert, Jordy Mehawej, Saberi Rana Ali, Carolyn Jeffcoat, Sergio Fonseca   +6 more
doaj   +1 more source

GMP Compliant Synthesis of Canagliflozin, a Novel PET Tracer for the Sodium−Glucose Cotransporter 2 [PDF]

, 2021
Inhibition of the sodium−glucose cotransporter 2 (SGLT2) by canagliflozin in type 2 diabetes mellitus results in large between-patient variability in clinical response. To better understand this variability, the positron emission tomography (PET) tracer [
Jacquet, Olivier, Stevens, Jasper, Heerspink, Hiddo J L, Antunes, Inês F., Antunes, Inês F, Elsinga, Philip H, Elsinga, Philip H., Visser, Ton J, Boersma, Hendrikus H., Antunes, Inês F; id_orcid, Boersma, Hendrikus H; id_orcid, Attia, Khaled A., Bulthuis, Marian, van Goor, Harry, Heerspink, Hiddo J. L., Zijlma, Rolf, van der Hoek, Sjoukje, Heeres, André, Attia, Khaled A, Stevens, Jasper; id_orcid, Visser, Ton J., van Goor, Harry; id_orcid, Boersma, Hendrikus H   +22 more
core   +3 more sources

Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis

Frontiers in Endocrinology
ObjectiveTo compare the effects of different selective sodium-glucose cotransporter-2 inhibitors (SGLT2i) on hemoglobin and hematocrit in patients with type 2 diabetes mellitus (T2DM) with a network meta-analysis (NMA).MethodsRandomized controlled trials
Yuanyuan Luo, Ruojing Bai, Wei Zhang, Guijun Qin   +3 more
doaj   +1 more source

Canagliflozin: A Review in Type 2 Diabetes. [PDF]

, 2017
peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Scheen, André, Deeks, Emma D., Emma D. Deeks, Emma D. Deeks (4985339), Andre Scheen (5037029), André J. Scheen   +5 more
core   +1 more source

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails

Сахарный диабет, 2022
The series of the cardiovascular outcome trails have demonstrated the nephroprotective properties of the gliflozins. Canagliflozin in the CREDENCE, which was the first study with a primary focus on the evaluation of the nephroprotective properties of ...
O. Y. Sukhareva, Z. T. Zuraeva, M. S. Shamhalova   +2 more
doaj   +1 more source